UCB SA (UCB) - Total Liabilities
Based on the latest financial reports, UCB SA (UCB) has total liabilities worth €7.29 Billion EUR as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
UCB SA - Total Liabilities Trend (2000–2025)
This chart illustrates how UCB SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
UCB SA Competitors by Total Liabilities
The table below lists competitors of UCB SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
E.ON SE
F:EOAN
|
Germany | €84.85 Billion |
|
Alimentation Couchen Tard Inc A
TO:ATD
|
Canada | CA$25.11 Billion |
|
OSRAM LICHT N
HM:OSR
|
Germany | €5.47 Billion |
|
Loblaw Companies Limited
TO:L
|
Canada | CA$30.39 Billion |
|
Mercedes-Benz Group AG
F:MBG
|
Germany | €164.91 Billion |
|
Ferguson Plc
NYSE:FERG
|
USA | $11.64 Billion |
|
L3Harris Technologies Inc
NYSE:LHX
|
USA | $21.48 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down UCB SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how UCB SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for UCB SA (2000–2025)
The table below shows the annual total liabilities of UCB SA from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €7.29 Billion | -0.37% |
| 2024-12-31 | €7.32 Billion | +11.49% |
| 2023-12-31 | €6.56 Billion | -3.53% |
| 2022-12-31 | €6.80 Billion | +16.83% |
| 2021-12-31 | €5.82 Billion | -3.69% |
| 2020-12-31 | €6.05 Billion | +48.50% |
| 2019-12-31 | €4.07 Billion | -4.39% |
| 2018-12-31 | €4.26 Billion | +1.87% |
| 2017-12-31 | €4.18 Billion | -11.70% |
| 2016-12-31 | €4.74 Billion | -12.48% |
| 2015-12-31 | €5.41 Billion | +2.89% |
| 2014-12-31 | €5.26 Billion | -3.29% |
| 2013-12-31 | €5.44 Billion | +14.05% |
| 2012-12-31 | €4.77 Billion | +9.46% |
| 2011-12-31 | €4.36 Billion | -0.50% |
| 2010-12-31 | €4.38 Billion | -6.93% |
| 2009-12-31 | €4.70 Billion | -14.60% |
| 2008-12-31 | €5.51 Billion | +4.08% |
| 2007-12-31 | €5.29 Billion | -7.50% |
| 2006-12-31 | €5.72 Billion | +147.83% |
| 2005-12-31 | €2.31 Billion | -32.29% |
| 2004-12-31 | €3.41 Billion | +160.76% |
| 2003-12-31 | €1.31 Billion | +23.83% |
| 2002-12-31 | €1.06 Billion | -10.05% |
| 2001-12-31 | €1.17 Billion | +6.95% |
| 2000-12-31 | €1.10 Billion | -- |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, … Read more